AAM slams USMCA trade deal

Failure to change provisions of the recently agreed US-Mexico- Canada Free Trade Agreement (USMCA) will “exacerbate the lagging biosimilar market in the US”, slow biosimilar and generic development, and create inconsistencies with US law, according to the US Association for Accessible Medicines (AAM).